-
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Friday, January 30, 2026 - 2:09pm | 670Read More...Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ:AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration. • Amgen stock is trading at elevated levels. Where are AMGN shares going? Kyowa Kirin will regain control of the global rocatinlimab program,...
-
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
Wednesday, January 14, 2026 - 1:36pm | 500Read More...At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc.(NASDAQ:AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment. • Amgen stock is showing positive momentum. What’s the outlook for AMGN shares? Key Findings...
-
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study
Monday, November 24, 2025 - 2:14pm | 643Read More...Bayer AG (OTC:BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian. • BMY shares are climbing. Find out why here. The study met its primary efficacy and safety endpoints. Asundexian 50 mg once daily...
-
Portola Pharma Shares Under Pressure After FDA Extension
Tuesday, December 26, 2017 - 11:18am | 440Read More...Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares are down Tuesday after the company's Friday announcement that the FDA has extended its review period for the biologics license application for AndexXa, an anticoagulant antidote product candidate, by 90 days. In August 2016, the...





